ChemoCentryx Inc (NASDAQ:CCXI) Treasurer Markus J. Cappel sold 86,311 shares of the company’s stock in a transaction dated Monday, January 13th. The stock was sold at an average price of $37.09, for a total value of $3,201,274.99. Following the transaction, the treasurer now directly owns 162,558 shares of the company’s stock, valued at $6,029,276.22. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

CCXI opened at $37.65 on Thursday. The business has a 50 day moving average price of $34.32 and a two-hundred day moving average price of $14.54. The company has a quick ratio of 3.12, a current ratio of 3.12 and a debt-to-equity ratio of 0.32. The company has a market cap of $2.20 billion, a PE ratio of -49.54 and a beta of 2.28. ChemoCentryx Inc has a 52 week low of $6.16 and a 52 week high of $39.80.

ChemoCentryx (NASDAQ:CCXI) last posted its quarterly earnings data on Monday, November 4th. The biopharmaceutical company reported ($0.22) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.28) by $0.06. The firm had revenue of $10.58 million during the quarter, compared to the consensus estimate of $7.83 million. ChemoCentryx had a negative return on equity of 88.76% and a negative net margin of 143.30%. As a group, sell-side analysts expect that ChemoCentryx Inc will post -0.98 EPS for the current fiscal year.

CCXI has been the subject of several analyst reports. JPMorgan Chase & Co. upped their price objective on ChemoCentryx from $14.00 to $28.00 and gave the stock a “positive” rating in a research report on Tuesday, November 26th. Zacks Investment Research downgraded ChemoCentryx from a “buy” rating to a “hold” rating in a report on Friday, January 3rd. Canaccord Genuity boosted their target price on ChemoCentryx from $16.00 to $48.00 and gave the company a “buy” rating in a report on Tuesday, November 26th. HC Wainwright boosted their target price on ChemoCentryx from $23.00 to $40.00 and gave the company a “buy” rating in a report on Tuesday, November 26th. Finally, BidaskClub downgraded ChemoCentryx from a “buy” rating to a “hold” rating in a report on Tuesday, January 7th. Three equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. ChemoCentryx currently has an average rating of “Buy” and an average target price of $40.29.

Hedge funds have recently modified their holdings of the company. Metropolitan Life Insurance Co NY raised its stake in shares of ChemoCentryx by 70.2% during the 3rd quarter. Metropolitan Life Insurance Co NY now owns 14,981 shares of the biopharmaceutical company’s stock worth $102,000 after buying an additional 6,177 shares in the last quarter. California Public Employees Retirement System grew its holdings in ChemoCentryx by 23.4% during the 3rd quarter. California Public Employees Retirement System now owns 46,126 shares of the biopharmaceutical company’s stock valued at $313,000 after buying an additional 8,735 shares during the last quarter. SG Americas Securities LLC grew its holdings in ChemoCentryx by 26.0% during the 3rd quarter. SG Americas Securities LLC now owns 25,418 shares of the biopharmaceutical company’s stock valued at $172,000 after buying an additional 5,247 shares during the last quarter. Vanguard Group Inc. grew its holdings in ChemoCentryx by 37.9% during the 2nd quarter. Vanguard Group Inc. now owns 1,774,489 shares of the biopharmaceutical company’s stock valued at $16,502,000 after buying an additional 488,063 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. grew its holdings in ChemoCentryx by 189.9% during the 2nd quarter. Charles Schwab Investment Management Inc. now owns 142,562 shares of the biopharmaceutical company’s stock valued at $1,326,000 after buying an additional 93,385 shares during the last quarter. 60.72% of the stock is owned by institutional investors and hedge funds.

About ChemoCentryx

ChemoCentryx, Inc, a clinical-stage biopharmaceutical company, develops new medications for inflammatory and autoimmune diseases, and cancer in the United States. The company targets the chemokine and chemoattractant systems to discover, develop, and commercialize orally-administered therapies. Its lead drug candidate is Avacopan, an orally-administered complement inhibitor of the complement C5a receptor (C5aR), is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis.

See Also: Why are percentage decliners important?

Insider Buying and Selling by Quarter for ChemoCentryx (NASDAQ:CCXI)

Receive News & Ratings for ChemoCentryx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChemoCentryx and related companies with MarketBeat.com's FREE daily email newsletter.